Regulatory expectations for patient input in drug development have shifted from aspiration to documented methodology across three major jurisdictions.
News|Webcasts|February 14, 2024
Transforming Clinical Trial Oversight with Generative AI
Author(s)IQVIA
Webinar Date/Time: Thursday, March 14th, 2024 at 11am EDT | 8am PDT | 3pm GMT | 4pm CET
Interested in how generative AI will impact clinical trial monitoring and sponsor oversight? Join IQVIA Technologies data and analytics experts to hear industry leading opinions and see generative AI in action.
Register Free:
Event overview
ICH E6 regulatory guidelines have driven significant change to clinical trial monitoring and sponsor oversight in the past few years. In turn, these new guidelines have been the impetus for new innovations in process and technology, bringing increased operational efficiency, risk management, and higher quality oversight to clinical trials.
Artificial intelligence (AI) is a key driver of change in the clinical trial industry enabling alignment with the new regulatory guidelines. More specifically, generative AI and Chat GPT are the new buzzwords that have garnered a tremendous amount of recent attention. This discussion will focus on the potential of generative AI to change, improve, and disrupt current approaches to monitoring and sponsor oversight of clinical trials. Join us to learn about how IQVIA’s Clinical Data Analytics Solutions (CDAS) is introducing conversational AI to analytics and transforming the approach to clinical trial oversight.
Three key take-aways
- Review and understand ICH E6 guidelines for sponsor oversight
- Discover the potential for generative AI to transform oversight
- Experience generative AI in action with IQVIA’s Clinical Analytics solution
Speakers:
Adrian Kizewski
Associate Director, Clinical Tech
IQVIA Technologies
Adrian has expertise in R&D and clinical life sciences, business analysis, process design and improvement, and product implementation. He is currently a lead for IQVIA’s Clinical Data Analytics Solution (CDAS), as well as Subpopulation Optimization and Modeling Solution (SOMS). Adrian holds an MBA from the McDonough School of Business at Georgetown University, an MSc in Pharmacology from The Johns Hopkins University School of Medicine, and a BSc in Biochemistry from Temple University.
Rathipriya Bhaskar
Sr Product Manager, Clinical Data Analytics
IQVIA Technologies
Rathi has over 18 years of experience in the IT industry, with more than a decade of experience managing and delivering cutting-edge software solutions for clinical trials while working through various systems in the trial landscape—including enterprise clinical data stores. Rathi is currently part of the product management group at IQVIA, leading the development for CDAS Clinical Analytics product powered with AI/ML capabilities.
Register Free:
Related to this article
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, explains why the full burden of developmental and epileptic encephalopathies extends far beyond clinical symptoms—and why endpoints must reflect what families are actually hoping for.
Participant engagement depends more on clarity and understanding than on gamification or incentives, requiring engagement embedded into trial workflows as a core design component rather than a peripheral consideration
In this video interview, Sylviane de Viron of CluePoints and Abigail Dirks of Tufts CSDD discuss what the RBQM financial model left out—reduced rework, improved data integrity, and inspection readiness—and why those excluded factors could represent even greater value than what was modeled.
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, outlines what it takes to move beyond transactional engagement and treat patient advocacy organizations as long-term partners in the science and the care.
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has learned firsthand from families living with Dravet syndrome and CDKL5 deficiency disorder about what makes trial participation possible—and what makes it not.
Clinical trials have spent decades perfecting data capture, but the execution layer underneath it, including decision workflows, data collection design, and lab connectivity, remains fragmented in ways that limit what AI can realistically deliver and that quietly compromise the scientific validity of the data itself.
Trending on Applied Clinical Trials Online
1
The Execution Gap: Why Clinical Trial Infrastructure Has to Be Built Before AI Can Deliver
2
The Evolution of Preclinical CRO Strategic Partnerships: From Transactional Services to Value-Driven Ecosystems in 2026
3
Benchmarking Study Finds Clinical Trial Performance Is Shaped by Operating Model Design, Not Sourcing Strategy
4
Operationalizing the Patient Voice: Converging U.S., EU, and UK Requirements and the Role of Real-World Patient-Reported Data
5